Feasibility Study on the FARAVIEW Technology

Inclusion Criteria:

1. Age: ≥ 18 years of age, or older if required by local law

2. Symptomatic, documented, drug-resistant, Atrial Fibrillation

3. Documented: at a minimum a physician's note confirming the arrhythmia symptomsand durations AND within 180 days of the Enrollment Date one (1) ECG from anyregulatory cleared rhythm monitoring device showing AF

4. Drug-resistant: effectiveness failure of, intolerance to, or specificcontraindication to at least one (1) AAD (Class I, II, III or IV) 1

5. Informed consent: willing and capable of providing informed consent

6. Full participation: willing and capable of participating in all follow-upassessments and testing associated with this clinical investigation at an approvedclinical investigational center

Exclusion Criteria:

1. Atrial exclusions - Any of the following atrial conditions:

2. Prior atrial ablation: any prior atrial endocardial, epicardial or surgicalablation procedure for arrhythmia other than ablation for right sided SVT orcavotricuspid isthmus ablation

3. Atrial myxoma: current atrial myxoma

4. Pulmonary veins: any PV abnormality, stenosis, or stenting (common and middlePVs are admissible)

5. Atrial thrombus: current left atrial thrombus

6. Long standing persistent AF: continuous AF lasting longer than 12 months

7. Cardiovascular exclusions - Any of the following CV conditions:

8. Ventricular arrhythmia: history of sustained ventricular tachycardia or anyventricular fibrillation

9. Secondary AF: AF that is secondary to electrolyte imbalance, thyroid disease,alcohol, or other reversible / non-cardiac causes

10. Cardiac devices and implants: current or anticipated pacemaker, implantablecardioverter defibrillator or cardiac resynchronization therapy devices,interatrial baffle, closure device, patch, or patent foramen ovale or ASDoccluder, LA appendage closure, device or occlusion.

11. Clinically significant valvular disease: valvular disease that is any of thefollowing: i. Symptomatic ii. Causing or exacerbating congestive heart failure iii. Associatedwith abnormal LV function or hemodynamic measurements e. Cardiomyopathy i.Hypertrophic cardiomyopathy ii. Cardiac amyloidosis f. Valve prostheses: anyprosthetic heart valve, ring or repair including balloon aortic valvuloplasty g.Access issues: any IVC filter, known inability to obtain vascular access or othercontraindication to femoral access h. Rheumatic disease: rheumatic heart disease i.Anticipated cardiac surgery: awaiting cardiac transplantation or other cardiacsurgery within the next 12 months

12. Any of the following conditions at baseline (Section 10.4):

13. Heart failure NYHA Heart failure associated with NYHA IV

14. Ejection fraction: LVEF < 40%

15. Any of the following events within 90 Days of the Consent Date:

16. Coronary disease: myocardial infarction (MI), unstable or coronary intervention

17. Cardiac surgery: any cardiac surgery

18. Heart failure hospitalization: heart failure hospitalization

19. Pericardium: pericarditis or symptomatic pericardial effusion

20. GI bleeding: gastrointestinal bleeding

21. Neurovascular event: stroke, TIA, or intracranial bleeding

22. Thromboembolism: any non-neurologic thromboembolic event

23. Carotid intervention: carotid stenting or endarterectomy

24. Bleeding diathesis: thrombocytosis, thrombocytopenia, disorder of blood clotting orbleeding diathesis

25. Contraindication to anticoagulation: contraindication to, or unwillingness to use,systemic anticoagulation

26. Pregnancy: women of childbearing potential who are pregnant, lactating, not usingmedical birth control or who are planning to become pregnant during the anticipatedstudy period

27. Health conditions that in the investigator's medical opinion would preventparticipation in the study, interfere with assessment or therapy, significantlyraise the risk of study participation, or modify outcome data or its interpretation,including but not limited to:

28. Obesity: Body Mass Index (BMI) > 45.0

29. Transplantation: solid organ or hematologic transplant, or currently beingevaluated for a transplant

30. Diaphragmatic abnormality: any prior history or current evidence ofhemi-diaphragmatic paralysis or paresis

31. Pulmonary: severe lung disease, pulmonary hypertension, or any lung diseaseinvolving abnormal blood gases or requiring supplemental oxygen

32. Renal: renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL / min / 1.73 m2, or with any history of renal dialysis or renaltransplant

33. Malignancy: active malignancy (other than cutaneous basal cell or squamous cellcarcinoma)

34. Gastrointestinal: clinically significant gastrointestinal problems involvingthe esophagus or stomach including severe or erosive esophagitis, uncontrolledgastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenalulceration

35. Infections: active systemic infection

36. COVID-19 disease: known positive test for COVID-19 and disease not clinicallyresolved

37. Life expectancy: predicted life expectancy less than one (1) year

38. Participation in another trial: subjects who are currently enrolled in anotherinvestigational study or registry that would directly interfere with the currentstudy, except when the subject is participating in a mandatory governmentalregistry, or a purely observational registry with no associated treatments; eachinstance must be brought to the attention of the Sponsor to determine eligibility

39. Congenital heart disease: congenital heart disease with any clinically significantresidual anatomic or conduction abnormality